

**298 patients assessed for eligibility:**

- a) Diagnosed with advanced or metastatic NSCLC**
- b) Had not receive any prior anti-tumor therapy**
- c) Treated with immunotherapy**

**Exclusion  
Criteria**

**9 patients lacked baseline or the alteration level of ChE;  
5 patients lacked efficacy and survival data;  
7 patients lost to follow-up**

**277 eligible patients included in the retrospective study**